Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1971 4
1972 2
1973 9
1974 25
1975 49
1976 70
1977 62
1978 54
1979 50
1980 52
1981 30
1982 35
1983 50
1984 54
1985 39
1986 59
1987 48
1988 65
1989 95
1990 127
1991 145
1992 219
1993 265
1994 364
1995 378
1996 419
1997 391
1998 410
1999 461
2000 421
2001 424
2002 406
2003 436
2004 462
2005 486
2006 480
2007 507
2008 488
2009 428
2010 446
2011 489
2012 470
2013 494
2014 480
2015 464
2016 543
2017 527
2018 511
2019 560
2020 587
2021 685
2022 637
2023 163
Text availability
Article attribute
Article type
Publication date

Search Results

14,374 results
Results by year
Filters applied: . Clear all
Page 1
Unique Effects of Clozapine: A Pharmacological Perspective.
Khokhar JY, Henricks AM, Sullivan EDK, Green AI. Khokhar JY, et al. Adv Pharmacol. 2018;82:137-162. doi: 10.1016/bs.apha.2017.09.009. Epub 2018 Jan 12. Adv Pharmacol. 2018. PMID: 29413518 Free PMC article. Review.
This chapter reviews clozapine's unique clinical effects and unusual pharmacological profile. ...We have suggested, from animal studies, that clozapine's apparent ability to limit substance use may occur through its actions as a weak dopamine D2 recept …
This chapter reviews clozapine's unique clinical effects and unusual pharmacological profile. ...We have suggested, from anima …
Clozapine as a Model for Antipsychotic Development.
Nucifora FC Jr, Mihaljevic M, Lee BJ, Sawa A. Nucifora FC Jr, et al. Neurotherapeutics. 2017 Jul;14(3):750-761. doi: 10.1007/s13311-017-0552-9. Neurotherapeutics. 2017. PMID: 28653280 Free PMC article. Review.
We further discuss the hypotheses for clozapine's superior efficacy based on neuroreceptor binding, and the limitations of a receptor-based approach to antipsychotic development. ...Finally, we examine how these approaches could provide insights into clozapine …
We further discuss the hypotheses for clozapine's superior efficacy based on neuroreceptor binding, and the limitations of a r …
Pharmacokinetics and pharmacodynamics of clozapine.
Jann MW, Grimsley SR, Gray EC, Chang WH. Jann MW, et al. Clin Pharmacokinet. 1993 Feb;24(2):161-76. doi: 10.2165/00003088-199324020-00005. Clin Pharmacokinet. 1993. PMID: 8453823 Review.
Clozapine is metabolised via the hepatic microsomal enzyme system into 2 principle metabolites: demethyl-clozapine and clozapine N-oxide. Urine samples have reported the ratio of clozapine:demethyl:N-oxide to be 1:1:2. The clozapine N-oxide bind …
Clozapine is metabolised via the hepatic microsomal enzyme system into 2 principle metabolites: demethyl-clozapine and cloz …
Clozapine in bipolar disorder: A systematic review and meta-analysis.
Delgado A, Velosa J, Zhang J, Dursun SM, Kapczinski F, de Azevedo Cardoso T. Delgado A, et al. J Psychiatr Res. 2020 Jun;125:21-27. doi: 10.1016/j.jpsychires.2020.02.026. Epub 2020 Feb 27. J Psychiatr Res. 2020. PMID: 32182485 Review.
RESULTS: Clozapine's efficacy was similar to other antipsychotics (Mean difference (MD): 0.03 [95%CI: 0.86-0.92], p = 0.59) in manic episodes. ...Sedation was the most frequent side effect (49.6%), followed by constipation (31.8%) and tachycardia (23.2%). CONCLUSION …
RESULTS: Clozapine's efficacy was similar to other antipsychotics (Mean difference (MD): 0.03 [95%CI: 0.86-0.92], p = 0.59) in …
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.
Kane J, Honigfeld G, Singer J, Meltzer H. Kane J, et al. Arch Gen Psychiatry. 1988 Sep;45(9):789-96. doi: 10.1001/archpsyc.1988.01800330013001. Arch Gen Psychiatry. 1988. PMID: 3046553 Clinical Trial.
This report describes a multicenter clinical trial to assess clozapine's efficacy in the treatment of patients who are refractory to neuroleptics. ...Patients whose condition remained unimproved were then randomly assigned, in a double-blind manner, to clozapine …
This report describes a multicenter clinical trial to assess clozapine's efficacy in the treatment of patients who are refract …
The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy.
Costa-Dookhan KA, Agarwal SM, Chintoh A, Tran VN, Stogios N, Ebdrup BH, Sockalingam S, Rajji TK, Remington GJ, Siskind D, Hahn MK. Costa-Dookhan KA, et al. Expert Opin Drug Saf. 2020 Jan;19(1):43-57. doi: 10.1080/14740338.2020.1698545. Epub 2019 Dec 2. Expert Opin Drug Saf. 2020. PMID: 31770500 Review.
However, ~40% of the patients respond insufficiently to clozapine. Clozapine's effects, both beneficial and adverse, have been proposed to be partially attributable to its main metabolite, N-desmethylclozapine (NDMC). ...The CLZ:NDMC ratio may be useful for p …
However, ~40% of the patients respond insufficiently to clozapine. Clozapine's effects, both beneficial and adverse, ha …
Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice.
Jendryka M, Palchaudhuri M, Ursu D, van der Veen B, Liss B, Kätzel D, Nissen W, Pekcec A. Jendryka M, et al. Sci Rep. 2019 Mar 14;9(1):4522. doi: 10.1038/s41598-019-41088-2. Sci Rep. 2019. PMID: 30872749 Free PMC article.
Muscarinic Designer Receptors Exclusively Activated by Designer Drugs (DREADD) gated by clozapine-N-oxide (CNO) allow selective G-protein cascade activation in genetically specified cell-types in vivo. Here we compare the pharmacokinetics, off-target effects and efficacy o …
Muscarinic Designer Receptors Exclusively Activated by Designer Drugs (DREADD) gated by clozapine-N-oxide (CNO) allow selective G-pro …
Clozapine, a fast-off-D2 antipsychotic.
Seeman P. Seeman P. ACS Chem Neurosci. 2014 Jan 15;5(1):24-9. doi: 10.1021/cn400189s. Epub 2013 Nov 18. ACS Chem Neurosci. 2014. PMID: 24219174 Free PMC article. Review.
The chemical structure of clozapine facilitates a relatively rapid dissociation from D2 receptors. ...Clozapine's transient occupation of D2 receptors permits patients to move easily and comfortably....
The chemical structure of clozapine facilitates a relatively rapid dissociation from D2 receptors. ...Clozapine's trans …
Clozapine.
Launer M. Launer M. Br J Hosp Med. 1993 Jan 6-19;49(1):56-8. Br J Hosp Med. 1993. PMID: 8431727 Review.
Clozapine is an atypical agent for intractable schizophrenia which was introduced into the UK at the beginning of 1990. Its lack of extrapyramidal side effects and its action on negative symptoms single it out from conventional neuroleptics. This article describes the drug …
Clozapine is an atypical agent for intractable schizophrenia which was introduced into the UK at the beginning of 1990. Its lack of e …
Clozapine.
[No authors listed] [No authors listed] Lancet. 1989 Dec 16;2(8677):1430-2. Lancet. 1989. PMID: 2574365 Review. No abstract available.
14,374 results
You have reached the last available page of results. Please see the User Guide for more information.